Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 13/20 | 0.54 |
| ▸ | TBXAS1 | P24557 | 8/20 | 0.54 |
| ▸ | ESR1 | P03372 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8825267 | 0.81 | L3MBTL1 (0.65) | — | |
| SCHEMBL10892857 | 0.80 | TBXA2R (0.74) | TBXA2RTBXAS1 | |
| SCHEMBL14596992 | 0.79 | ALDH1A1 (0.50) | TBXA2RTBXAS1 | |
| SCHEMBL1284358 | 0.79 | TBXA2R (0.79) | TBXA2RTBXAS1 | |
| SCHEMBL4961384 | 0.79 | TBXA2R (0.49) | TBXA2RTBXAS1ESR1 | |
| SCHEMBL1115654 | 0.79 | HTR1B (0.51) | TBXA2RTBXAS1ESR1 | |
| SCHEMBL9514911 | 0.78 | TBXA2R (0.48) | TBXA2RTBXAS1ESR1 | |
| SCHEMBL22946578 | 0.78 | PPARG (0.59) | TBXA2RTBXAS1ESR1 | |
| SCHEMBL27835726 | 0.77 | PPARG (0.48) | TBXA2RTBXAS1ESR1 | |
| SCHEMBL30228503 | 0.76 | TBXA2R (0.50) | TBXA2RTBXAS1ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1898917-B1 | AMINOPYRIMIDINES AS KINASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-01-14 | — | — | EP | disclosed |
| EP-1898917-B1 | AMINOPYRIMIDINES AS KINASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-01-14 | — | — | EP | disclosed |
| EP-1901745-A2 | SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOPYRIMIDINES KINASE MODULATORS AND A FARNESYL TRANSFERASE INHIBITOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-26 | — | — | EP | disclosed |
| US-20070021435-A1 | AMINOPYRIMIDINES AS KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-01-25 | — | — | US | disclosed |
| US-20070021435-A1 | AMINOPYRIMIDINES AS KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-01-25 | — | — | US | disclosed |
| US-20070021435-A1 | AMINOPYRIMIDINES AS KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-01-25 | — | — | US | disclosed |
| WO-2006135713-A2 | SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOPYRIMIDINES KINASE MODULATORS AND A FARNESYL TRANSFERASE INHIBITOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-21 | — | — | WO | disclosed |
| US-20060281755-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOPYRIMIDINES KINASE MODULATORS | BAUMANN CHRISTIAN A | 2006-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021435-A1 | AMINOPYRIMIDINES AS KINASE MODULATORS | FLT3, KIT, TK1 | TBXA2R 1317/4885TBXAS1 1213/4885ESR1 1714/4885 |
| US-20060281755-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOPYRIMIDINES KINASE MODULATORS | FLT3, CSF3R, CSF1R | TBXA2R 3088/4885TBXAS1 1410/4885ESR1 2950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.